Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epigenetic backbone plus DEL chemotherapy for relapsed or refractory pediatric T-ALL/T-NHL
ChiCTR2200058721Phase 4Not yet recruiting
- Sponsor
- Children's Hospital of Soochow University
- Start
- Apr 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tucidinostat, venetoclax, decitabine, azacitidine, dexamethasone and 2 more in t-cell acute lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LBL), sponsored by Children's Hospital of Soochow University. Primary endpoints: Complete remission, Partial remission and 1 more. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
tucidinostatvenetoclaxdecitabineazacitidinedexamethasone
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T-lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on ChiCTR2200058721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058721.